2024-11-12T14:09:01-06:00 2023-12-31 872525370 CITRIN COOPERMAN ADVISORS LLC 50 ROCKEFELLER PLAZA NEW YORK NY 10020 990 2023-01-01 141935776 LUNG CANCER RESEARCH FOUNDATION LUNG 2125881580 501 7TH AVENUE 230 NEW YORK NY 10018 AUBREY RHODES EXECUTIVE DIRECTOR 2125881580 2024-11-11 1 1 AMANDA ADAMS P00748038 2126971000 2024-11-11 2023 2024-10-15 13:58:12Z AUBREY RHODES 501 7TH AVENUE 230 NEW YORK NY 10018 6773322 0 X WWW.LCRF.ORG X 2005 NY THE MISSION OF THE LUNG CANCER RESEARCH FOUNDATION IS TO IMPROVE LUNG CANCER OUTCOMES BY FUNDING RESEARCH FOR THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF LUNG CANCER. 14 14 21 97 0 0 7013446 6148851 0 0 28829 212398 -438719 25923 6603556 6387172 3052308 2481669 0 0 2157339 2473909 127467 0 759132 1219816 1467868 6556930 6423446 46626 -36274 5557342 6946397 1973122 3310501 3584220 3635896 X THE MISSION OF THE LUNG CANCER RESEARCH FOUNDATION IS TO IMPROVE LUNG CANCER OUTCOMES BY FUNDING RESEARCH FOR THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF LUNG CANCER. 0 0 3429071 2481669 RESEARCH: EACH YEAR, LCRF AWARDS RESEARCH GRANTS TO RECIPIENTS AROUND THE WORLD THAT DEMONSTRATE PROMISE AND INGENUITY IN THEIR WORK. INVESTIGATORS ARE SELECTED FROM HUNDREDS OF APPLICANTS AND REPRESENT SOME OF THE BRIGHTEST MINDS COMMITTED TO IMPROVING OUTCOMES FOR LUNG CANCER PATIENTS. THEY COME FROM VARIOUS CAREER PATHS INCLUDING SCIENTISTS, PHYSICIANS, STUDENTS, AND FELLOWS, AND WORKING ON A VARIETY OF INNOVATIVE RESEARCH PROJECTS RELATED TO LUNG CANCER RESEARCH.SEE SCHEDULE O FOR ADDITIONAL INFORMATION. 1911609 PATIENT EDUCATION & OUTREACH: WE PROVIDE UP-TO-DATE AND CREDIBLE SOURCES OF INFORMATION ON DIAGNOSIS, TREATMENT, AND WHAT TO EXPECT FROM TREATMENT THROUGH OUR FREE EDUCATIONAL MATERIALS. WE ALSO HAVE TOOLS TO HELP YOU FACILITATE DISCUSSIONS WITH YOUR HEALTHCARE TEAM SO YOU CAN PLAY AN ACTIVE ROLE IN TREATMENT DECISIONS. OUR MATERIALS ARE AVAILABLE IN BOTH DIGITAL DOWNLOAD AND PRINT FORMAT.SEE SCHEDULE O FOR ADDITIONAL INFORMATION. 5340680 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 22 0 1 21 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 14 14 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NY AL AR FL GA KS KY ME MD MA MI MN HI NH NJ NC TN UT VA SC OR ND WA WV WI MS AK CA CO CT IL NM OH OK PA RI X X KELLY BULLOCK 2125881580 501 7TH AVE SUITE 230 NEW YORK NY 10018 REINA HONTS CHAIR/VICE CHIAR 5.00 X X 0 0 0 BRENDON M STILES MD VICE CHAIR 3.00 X X 0 0 0 MARY ANN TIGHE VICE CHAIR 3.00 X X 0 0 0 AARON M TIGHE TREASURER 3.00 X X 0 0 0 KATERINA POLITI PHD DIRECTOR 1.00 X 0 0 0 JOAN H SCHILLER MD DIRECTOR 1.00 X 0 0 0 RAY E CHALME DIRECTOR 1.00 X 0 0 0 BRUCE DUNBAR SECRETARY 1.00 X X 0 0 0 PETER FRY DIRECTOR 1.00 X 0 0 0 JILL FURMAN DIRECTOR 1.00 X 0 0 0 SCOTT MORRIS DIRECTOR 1.00 X 0 0 0 MATTHEW CIPRIANI DIRECTOR 1.00 X 0 0 0 ROSE ANN WEINSTEIN DIRECTOR 1.00 X 0 0 0 COLEEN CONNOR-ZIEGLER CHAIR 1.00 X X 0 0 0 DENNIS CHILLEMI EXECUTIVE DIRECTOR 40.00 X 145246 0 5570 TONEL RODGERS DIRECTOR, FINANCE & ADMINISTRATION 40.00 X 127063 0 17462 ANTOINETTE WOZNIAK CHIEF SCIENTIFIC OFFICER 40.00 X 194635 0 28354 AUBREY RHODES SENIOR VP, STRATEGY 40.00 X 182764 0 18206 SHEILA SULLIVAN SR. DIRECTOR, MARKETING & COMMUNICATION 40.00 X 133277 0 32049 STACEY BOWERS SR. DIRECTOR, COMMUNITY EN 40.00 X 130973 0 40836 NATALIE REILLY-FINCH SR. DIRECTOR OF DONOR DEVELOPMENT 40.00 X 135000 0 3738 1048958 0 146215 7 0 1 0 CONRAD & ASSOCIATES LLC 11105 TARA RD POTOMAC MD 20854 MARKETING 155000 1 1853459 4295392 6148851 212398 212398 412073 1853459 386150 25923 25923 6387172 0 0 238321 2481669 2481669 506572 402484 30163 73925 1460768 1078683 163722 218363 20362 10057 4531 5774 331076 247857 33462 49757 155131 116348 15513 23270 108301 100947 7354 46020 17501 19770 8749 214167 193467 8280 12420 196216 196216 179553 155641 1430 22482 219303 164477 21931 32895 75839 56880 7584 11375 69321 65854 3467 14761 14023 738 21964 16473 2196 3295 BAD DEBTS 202023 202023 BANK FEES 85672 3493 82179 PROGRAM MATERIALS 22103 22103 STATE FILING FEES 12625 12625 6423446 5340680 323634 759132 X 33893 13557 0 20336 357492 669589 3426938 5298125 1506082 732857 600 121571 140415 55000 55000 0 0 145259 104811 5557342 6946397 242499 419291 1567602 2423603 32735 401269 130286 66338 1973122 3310501 X 2427004 1662625 1157216 1973271 3584220 3635896 5557342 6946397 X -36274 87950 X 0 1 X 1 0 X 5916763 5465693 6344359 7013446 6148851 30889112 5916763 5465693 6344359 7013446 6148851 30889112 5557884 25331228 3178 1357 1402 28829 212398 247164 25923 25923 31162199 9780 0.81290 0.84950 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 55000 55000 0 0 OPERATING LEASE LIABILITIES 66338 66338 X 6400790 13618 13618 6387172 0 6387172 6349114 13618 13618 6335496 87950 87950 6423446 PART X, LINE 2: THE FOUNDATION RECOGNIZES AND MEASURES ITS UNRECOGNIZED TAX BENEFITS IN ACCORDANCE WITH FASB ASC 740, INCOME TAXES. UNDER THAT GUIDANCE, THE FOUNDATION ASSESSES THE LIKELIHOOD, BASED ON THEIR TECHNICAL MERIT, THAT TAX POSITIONS WILL BE SUSTAINED UPON EXAMINATION BASED ON THE FACTS, CIRCUMSTANCES AND INFORMATION AVAILABLE AT THE END OF EACH PERIOD. THE MEASUREMENT OF UNRECOGNIZED TAX BENEFITS IS ADJUSTED WHEN NEW INFORMATION IS AVAILABLE, OR WHEN AN EVENT OCCURS THAT REQUIRES A CHANGE. MANAGEMENT HAS EVALUATED THE FOUNDATION'S TAX POSITIONS AND BELIEVES THAT THE FOUNDATION HAS TAKEN NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE ADJUSTMENTS TO THE FINANCIAL STATEMENTS. PART XII, LINE 4B - OTHER ADJUSTMENTS: RETURNED GRANT FUNDS NETTED AGAINST EXPENSE 87,950. ELLIOT'S LEGACY 446420 446420 2880 124759 GALA 565338 392338 173000 77264 46528 10 1253774 1014701 239073 1268 133451 2265532 1853459 412073 81412 304738 386150 25923 1 BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA HOUSTON TX 77030 741613878 501(C)(3) 12810 0 RESEARCH DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 042263040 501(C)(3) 10675 0 RESEARCH DARTMOUTH-HITCHCOCK CLINICAL TRIALS ONE MEDICAL CENTER DRIVE LEBANON NH 03756 222519596 501(C)(3) 10675 0 RESEARCH DUKE UNIVERSITY PO BOX 104132 DURHAM NC 27708 560532129 501(C)(3) 149923 0 RESEARCH H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL INC PO BOX 406249 ATLANTA GA 30384 593238634 501(C)(3) 10675 0 RESEARCH LOYOLA UNIVERSITY OF CHICAGO 820 N MICHIGAN AVE CHICAGO IL 60611 361408475 501(C)(3) 268973 0 RESEARCH MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 160675 0 RESEARCH MAYO CLINIC 200 FIRST STREET SW ROCHESTER ME 55905 416011702 501(C)(3) 150000 0 RESEARCH MD ANDERSON CANCER CENTER 1515 HOLCOMBE BOULEVARD HOUSTON TX 77030 746001118 501(C)(3) 504106 0 RESEARCH MEDICAL UNIVERSITY OF SOUTH CAROLINA 1 SOUTH PARK CIRCLE BUILDING 1 STE 402 CHARLESTON CHARLESTON SC 29407 576000722 501(C)(3) 10675 0 RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 176000 0 RESEARCH NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 362167817 501(C)(3) 10675 0 RESEARCH REGENTS OF UNIVERSITY OF MICHIGAN 5082 WOLVERINE TOWER 3003 SOUTH STATE STREET ANN ARBOR MI 48109 386006309 501(C)(3) 14945 0 RESEARCH THE BRIGHAM & WOMEN'S HOSPITAL INC PO BOX 3149 BOSTON MA 02241 042312909 501(C)(3) 10675 0 RESEARCH THE CURATORS OF THE UNIVERSITY OF MISSOURI 118 UNIVERSITY HALL COLUMBIA MT 65211 436003859 501(C)(3) 53375 0 RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94143 946036493 501(C)(3) 150000 0 RESEARCH THE UNIVERSITY OF ALABAMA 801 5TH AVE SOUTH ROOM 251 BIRMINGHAM AL 35233 636005396 501(C)(3) 269222 0 RESEARCH TRUSTEES OF BOSTON UNIVERSITY 881 COMMONWEALTH AVENUE BOSTON MA 02215 042103547 501(C)(3) 150000 0 RESEARCH UC DAVIS COMPREHENSIVE CANCER CENTER 1 SHIELDS AVENUE DAVIS CA 95616 946036494 501(C)(3) 10675 0 RESEARCH UCLA 10889 WILSHIRE BLVD SUITE 1100 LOS ANGELES CA 90024 952250801 501(C)(3) 40565 0 RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER DEPT 1236 PO BOX 121236 DALLAS TX 75312 352528741 501(C)(3) 135000 0 RESEARCH VIRGINIA CANCER SPECIALISTS PC 3040 WILLIAMS DRIVE SUITE 100 FAIRFAX VA 22031 541795091 501(C)(3) 10675 0 RESEARCH WASHINGTON UNIVERSITY IN ST LOUIS PO BOX 505505 ST LOUIS MT 63150 430653611 501(C)(3) 10675 0 RESEARCH YALE UNIVERSITY OFFICE OF SPONSORED PROJECTS PO BOX 1873 NEW HAVEN CT 06508 060646973 501(C)(3) 150000 0 RESEARCH 27 0 PART I, LINE 2: APPLICATIONS TO LCRF'S SCIENTIFIC GRANT PROGRAM ARE REVIEWED VIA A THREE-PART PROCESS. THEY ARE FIRST SCREENED BY LCRF STAFF TO ENSURE COMPLETENESS AND COMPLIANCE WITH ELIGIBILITY CRITERIA, BUDGET, AND OTHER SUBMISSION REQUIREMENTS. THE APPLICATIONS ARE NEXT SCREENED FOR SCIENTIFIC RATIONALE, CREATIVITY, APPROPRIATENESS OF TIMELINES AND BUDGET, INSTITUTIONAL LETTERS OF SUPPORT AND IMPACT ON THE FIELD OF LUNG CANCER RESEARCH BY THE LCRF SCIENTIFIC ADVISORY BOARD (SAB). NEXT, A SET OF SEMI-FINALISTS ARE INDEPENDENTLY AND COMPREHENSIVELY REVIEWED BY SUBCOMMITTEES OF THREE EXPERTS FROM THE SAB AND SCORED BY STANDARD NIH/NCI CRITERIA. UPON COMPLETION OF THE REVIEW PROCESS, APPLICATIONS ARE RANKED IN ORDER FROM HIGHEST TO LOWEST-SCORING, AND PROPOSALS SELECTED TO BE CONSIDERED FOR FUNDING ARE CHOSEN BASED STRICTLY ON THE APPLICATION SCORES - NO EXTERNAL REVIEW IS ALLOWED. CURRENTLY FUNDED PROJECTS ARE EVALUATED ON AN ANNUAL BASIS WITH AN ASSESSMENT OF A PROGRESS REPORT. X X 0 0 0 0 0 0 0 0 0 ANTOINETTE WOZNIAK CHIEF SCIENTIFIC OFFICER 194635 0 0 0 0 0 0 0 28354 0 222989 0 0 0 AUBREY RHODES SENIOR VP, STRATEGY 182764 0 0 0 0 0 7448 0 10758 0 200970 0 0 0 STACEY BOWERS SR. DIRECTOR, COMMUNITY EN 130973 0 0 0 0 0 5400 0 35436 0 171809 0 0 0 SHEILA SULLIVAN SR. DIRECTOR, MARKETING & COMMUNICAT 133277 0 0 0 0 0 5427 0 26622 0 165326 0 0 0 DENNIS CHILLEMI EXECUTIVE DIRECTOR 145246 0 0 0 0 0 5570 0 0 0 150816 0 0 0 FORM 990, PART III LINE 4A, PROGRAM SERVICE ACCOMPLISHMENTS: RESEARCH: DESPITE BEING THE LEADING CAUSE OF CANCER MORTALITY, LUNG CANCER RECEIVES FAR LESS RESEARCH FUNDING PER DEATH. LUNG CANCER RECEIVES $3,580 PER DEATH COMPARED TO BREAST CANCER AT $19,050, PROSTATE CANCER AT $8,116, AND PANCREATIC CANCER AT $4,796. THAT IS WHY FUNDING FROM NON-GOVERNMENTAL ORGANIZATIONS IS SO CRITICAL. THE LUNG CANCER RESEARCH FOUNDATION (LCRF) PLAYS A PIVOTAL ROLE IN THIS FUNDING LANDSCAPE. SINCE 2005, THE LUNG CANCER RESEARCH FOUNDATION, AND ITS PROGENITOR ORGANIZATIONS, HAS BEEN COMMITTED TO FUNDING CUTTING EDGE RESEARCH THAT TRANSFORMS THE LUNG CANCER TREATMENT LANDSCAPE. WHEN WE FIRST OPENED OUR DOORS, OUR MISSION WAS SIMPLE: PROVIDE HOPE BY FUNDING THE BEST RESEARCH AND HELP BRING IT TO PEOPLE. WE HAVE BEEN WILDLY SUCCESSFUL. IN 18 YEARS, WE HAVE BECOME ONE OF THE LARGEST PRIVATE FUNDERS OF LUNG CANCER RESEARCH ENABLING EARLIER DETECTION, DEEPER UNDERSTANDING OF THE MECHANISMS THAT ALLOW LUNG CANCER TO FORM, AND NEW AND EXPANDED TREATMENT OPTIONS THAT HAVE SAVED MANY LIVES. SIMULTANEOUSLY, OUR SCIENTIFIC ADVISORY BOARD HAS BECOME ONE OF THE PREEMINENT BODIES IN THE LUNG CANCER RESEARCH COMMUNITY. FURTHERMORE, OUR INVESTMENT IN EARLY CAREER INVESTIGATORS CONTINUES TO ALLOW NEW TALENT TO THRIVE AND GROW IN THE SPACE AS IS DEMONSTRATED THROUGH FOLLOW-ON FUNDING MANY HAVE RECEIVED SINCE RECEIVING THEIR LCRF GRANT. TO DATE, LCRF HAS PROVIDED 419 RESEARCH GRANTS TOTALING NEARLY $44 MILLION, THE LARGEST AMOUNT PROVIDED BY A NON-GOVERNMENTAL ORGANIZATION DEDICATED TO FUNDING LUNG CANCER RESEARCH. SUPPORT WITHIN THE PATIENT COMMUNITY, RESEARCHERS, STRATEGIC PARTNERS, AND INDUSTRY PARTNERS IS KEY TO OUR PRESENT SUCCESS AS WELL AS ACHIEVING OUR FUTURE VISION TO FIND A CURE FOR LUNG CANCER. DURING 2023, WE FUNDED TEN (10) RESEARCH GRANTS ACROSS FIVE (5) RESEARCH GRANT TRACKS. TWO (2) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF LEADING EDGE RESEARCH GRANT PROGRAM WHICH FUNDS INNOVATIVE PROJECTS ACROSS THE FULL SPECTRUM OF BASIC, TRANSLATIONAL, CLINICAL, EPIDEMIOLOGICAL, HEALTH SERVICES, AND RESEARCH FOCUSED ON A MYRIAD OF TOPICS. THE PROJECTS WILL EXPLORE THE FOLLOWING: - INVESTIGATING NOVEL SYNTHETIC LETHAL VULNERABILITIES IN EGFR-DRIVEN LUNG CANCER - DEEP WHOLE GENOME SEQUENCING OF CIRCULATING TUMOR DNA FOR STUDYING EVOLUTION AND THERAPY RESISTANCE IN SMALL CELL LUNG CANCER TWO (2) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF RESEARCH GRANT ON UNDERSTANDING RESISTANCE IN LUNG CANCER. THESE PROJECTS WILL FOCUS ON UNDERSTANDING THE DEVELOPMENT, PREVENTION, AND THERAPY OF RESISTANCE BY SUPPORTING PROJECTS THAT ARE IDENTIFYING, CHARACTERIZING, TREATING OR PREVENTING RESISTANCE TO THERAPIES IN LUNG TUMOR CELLS, TISSUES, MOUSE MODELS, AND/OR PATIENTS. THESE STUDIES WILL ENHANCE THE MOMENTUM OF IMPROVING LUNG CANCER OUTCOMES AND HAVE THE POTENTIAL TO INCREASE SURVIVORSHIP. THESE PROJECTS WILL EXPLORE THE FOLLOWING: - CHARACTERIZATION AND THERAPEUTIC TARGETING OF A TUMOR-TUMOR MICROENVIRONMENT NETWORK PROMOTING RESISTANCE TO TARGETED THERAPY IN LUNG CANCER - UNCOVERING NOVEL VULNERABILITIES TO TREAT SCLC THERAPY RESISTANCE TWO (2) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF MINORITY CAREER DEVELOPMENT AWARD (CDA). MINORITY APPLICANTS ARE LESS LIKELY TO RECEIVE GRANTS, TO HAVE THE R PHASES OF K01 OR K99 AWARDS ACTIVATED, NEED MORE SUBMISSIONS TO OBTAIN FUNDING, AND OFTEN WILL NOT RESUBMIT PROPOSALS. AS MINORITY APPLICANTS MUST OVERCOME SYSTEMIC AND STRUCTURAL BARRIERS DUE TO RACE, ETHNICITY, COUNTRY OF ORIGIN, SOCIOECONOMIC STATUS, AND/OR LANGUAGE, MANY LEAVE ACADEMIA WHICH FURTHER EXACERBATES THE LACK OF DIVERSITY IN SCIENCE, TECHNOLOGY, ENGINEERING AND MATHEMATICS (STEM) AND MEDICAL FIELDS. TO PROVIDE PROTECTED TIME AND MENTORING TO THESE TRAINEES, WE CONTINUE TO OFFER THE LCRF MINORITY CAREER DEVELOPMENT AWARD (CDA) FOR LUNG CANCER FOR MINORITY POSTDOCTORAL/CLINICAL FELLOWS AND ASSISTANT PROFESSORS WITHIN 10 YEARS OF COMPLETING THEIR MD AND/OR PHD DEGREES TO SUBMIT PROPOSALS. THE PROJECTS WILL EXPLORE THE FOLLOWING: - HARNESSING B CELL SPECIFIC CHECKPOINT MOLECULES IN LUNG CANCER - IMPACT OF SENESCENT CELLS ON LUNG TUMORIGENESIS ONE (1) RESEARCH GRANT WAS FUNDED THROUGH THE LCRF RESEARCH GRANT ON EARLY DETECTION AND PRE-NEOPLASIA IN LUNG CANCER. GIVEN THE SIGNIFICANCE AND NEED FOR EARLY DETECTION OF LUNG CANCER AND ADVANCEMENTS IN MOLECULAR SCREENING, LCRF CONTINUES TO OFFER A FUNDING MECHANISM TO SUPPORT RESEARCH PROJECTS THAT FACILITATE OR ADVANCE THE UNDERSTANDING AND CHARACTERIZATION OF PRE-NEOPLASIA OR APPROACHES FOR EARLY DETECTION OF LUNG CANCER. WORK SUPPORTED THROUGH THIS MECHANISM ADDRESSES IMPORTANT QUESTIONS IN NON-SMALL CELL AND SMALL CELL LUNG CANCER. THE PROJECTS WILL EXPLORE THE FOLLOWING: - THE SPATIAL B CELL LANDSCAPE IN LUNG SQUAMOUS PREMALIGNANT LESION THREE (3) RESEARCH GRANTS WERE FUNDED THROUGH THE LCRF-DAIICHI SANKYO-ASTRAZENECA RESEARCH GRANT ON ANTIBODY DRUG CONJUGATES, SUPPORTING RESEARCH TO STUDY HER2 DIRECTED AND TROP2 DIRECTED ADCS INCLUDING MECHANISM OF ACTION, BIOMARKERS, AND RESISTANCE MECHANISMS. THE PROJECTS WILL EXPLORE THE FOLLOWING: - DECIPHERING THE ADC CODE: A PROTEOGENOMIC QUEST IN LUNG CANCER - PULMONARY HIGH-GRADE NEUROENDOCRINE CARCINOMAS AS INDICATIONS FOR ANTIBODY-DRUG CONJUGATES TARGETING TROP2 AND HER2 - LEVERAGING LIQUID BIOPSY TO IDENTIFY THE OPTIMAL CLINICAL NICHE FOR TROP2-TARGETING IN NSCLC IN ADDITION, THE FOUNDATION IS CURRENTLY ADMINISTRATING RESEARCH PARTNERSHIPS WITH THE LUNG CANCER MUTATION CONSORTIUM. LCRF'S PARTNERSHIP WITH THE LUNG CANCER MUTATION CONSORTIUM (LCMC) DATES BACK TO 2011 COVERING THREE CLINICAL TRIALS. THE LCMC2 CLINICAL TRIAL ENROLLED 1,000 PATIENTS VIA A NETWORK OF FOURTEEN (14) NOTABLE DOMESTIC CLINICAL RESEARCH SITES. THE CLINICAL TRIAL STUDIED THE IMPACT OF SMOKING AND TP53 MUTATIONS IN LUNG ADENOCARCINOMA PATIENTS WITH TARGETABLE MUTATIONS. THE LCMC3 CLINICAL TRIAL BEGAN IN 2017 AND HAS ENROLLED 1,000 PATIENTS VIA A NETWORK OF FIVE (5) DOMESTIC CLINICAL RESEARCH SITES. LCMC3 IS DESIGNED AS A NEOADJUVANT AND ADJUVANT TRIAL OF IMMUNE CHECKPOINT BLOCKADE FOR STAGE IB-IIIA NON-SMALL CELL LUNG CANCER. FINAL REPORTING FROM THIS CLINICAL TRIAL SHOULD BE COMPLETED IN LATE 2024. LAUNCHED IN LATE 2020, LCMC4 IS A STUDY WITH A GOAL OF ENLISTING 1,000 PATIENTS VIA A NETWORK OF 25+ DOMESTIC CLINICAL RESEARCH SITES. THE AIM OF THE CLINICAL TRIAL IS TO DETERMINE THE FEASIBILITY OF COMPREHENSIVE MOLECULAR PROFILING TO DETECT ACTIONABLE ONCOGENIC DRIVERS IN PATIENTS WITH SUSPECTED EARLY-STAGE LUNG CANCERS SCHEDULED TO UNDERGO BIOPSIES TO ESTABLISH THE DIAGNOSIS OF LUNG CANCER. SEVEN (7) GRANTS IN SUPPORT OF THE LCMC4 - LEADER NEOADJUVANT SCREENING TRIAL HAVE BEEN MADE. IN 2023, OUR RESEARCH INVESTMENT WAS FUNDED WITHOUT THE NEED FOR DEFICIT SPENDING, AND WE ARE POISED TO GROW OUR RESEARCH INVESTMENT IN THE COMING YEARS. FORM 990, PART III LINE 4B, PROGRAM SERVICE ACCOMPLISHMENTS: PATIENT EDUCATION & OUTREACH: THE PATIENT EDUCATION PORTFOLIO INCLUDES PRINT AND DIGITAL EDUCATIONAL RESOURCES (PDF DOWNLOADABLE FORMAT AS WELL AS EASILY ACCESSIBLE WEBSITE CONTENT) THAT ARE PROVIDED AT NO COST. THE OVERALL GOALS OF OUR PATIENT EDUCATION MATERIALS ARE TO HELP PATIENTS AND THEIR FAMILIES BETTER UNDERSTAND LUNG CANCER, LEARN ABOUT TREATMENT OPTIONS, PARTICIPATE IN SHARED DECISION MAKING WITH THEIR CARE TEAM, MAKE DECISIONS ABOUT CLINICAL TRIALS, AND UNDERSTAND THE IMPLICATIONS OF COMPREHENSIVE BIOMARKER TESTING. PATIENTS AND CAREGIVERS NEED INFORMATION AT ALL STEPS IN THE CONTINUUM OF CARE, FROM DIAGNOSIS THROUGH TREATMENT AND BEYOND. THE LUNG CANCER RESEARCH FOUNDATION HAS A PORTFOLIO OF EDUCATIONAL RESOURCES TO HELP PATIENTS AND THEIR FAMILIES BETTER UNDERSTAND LUNG CANCER AND LEARN ABOUT THEIR TREATMENT OPTIONS. HELPING PATIENTS TO UNDERSTAND NEW TREATMENTS AND THE HOPE OFFERED BY THESE TREATMENT ADVANCES ARE KEY OBJECTIVES OF OUR EDUCATIONAL MATERIALS. WE ALSO HAVE MATERIALS DESIGNED TO EDUCATE THE PUBLIC ABOUT THE MAGNITUDE OF LUNG CANCER AS A HEALTH CARE PROBLEM AND WAYS TO IDENTIFY SYMPTOMS OF THE DISEASE. IN 2023, LCRF DISTRIBUTED OVER 184,000 EDUCATIONAL PIECES TO LUNG CANCER PATIENTS, CAREGIVERS, ADVOCATES AND HEALTHCARE PROFESSIONALS ACROSS THE NATION IN BOTH PRINT AND DIGITAL FORMAT. OUR WEBSITE ALSO CONTAINS LINKS TO INFORMATION AND RESOURCES, WHICH RECEIVES ON AVERAGE OF MORE THAN 200,000 PAGEVIEWS ANNUALLY. OUR CONTINUED GOAL IS TO STEADILY INCREASE OUR MATERIALS DISTRIBUTED, PARTICULARLY WITH DIGITAL DOWNLOADS AS THERE HAS BEEN A SURGE IN DEMAND FOR READILY AVAILABLE INFORMATION. THE KEY OBJECTIVES OF THE PORTFOLIO ARE TO: EMPOWER PATIENTS AND CAREGIVERS BY INCREASING THEIR KNOWLEDGE OF LUNG CANCER, BIOMARKER TESTING, CLINICAL TRIALS AND TREATMENT OPTIONS; PROVIDE AN UP-TO-DATE AND CREDIBLE SOURCE OF INFORMATION ON AVAILABLE TREATMENTS, EDUCATE PATIENTS ON WHAT TO EXPECT FROM TREATMENT AND WHAT IS CRITICAL FOR OPTIMAL OUTCOMES; PROVIDE TOOLS TO FACILITATE DISCUSSIONS BETWEEN PATIENTS AND HEALTHCARE PROVIDERS; EDUCATE THE PUBLIC ABOUT THE MAGNITUDE OF LUNG CANCER AS A HEALTH CARE ISSUE, WAYS TO IDENTIFY SYMPTOMS OF THE DISEASE, AND EXPLAIN THE IMPORTANCE OF EARLY DETECTION, TUMOR BIOMARKER TESTING AND CLINICAL TRIAL PARTICIPATION; SHARE PROGRESS AND IMPACT OF RESEARCH (INCLUDING THAT WHICH IS FUNDED BY LCRF), AND EXPLAIN WHY FUNDING RESEARCH IS CRUCIAL FOR THE DEVELOPMENT OF NEW TREATMENTS FOR LUNG CANCER; AND ENSURE THAT THE MATERIALS ARE CULTURALLY APPROPRIATE, AT APPROPRIATE LITERACY LEVELS, AND ACCESSIBLE THROUGH A VARIETY OF DELIVERY METHODS (ONLINE, THROUGH COMMUNITY GROUPS AND COMMUNITY HEALTHCARE PROVIDERS, PATIENT AND CAREGIVER FOCUSED EVENTS, ETC.). THE PATIENT EDUCATION MATERIALS ARE EVIDENCE-BASED AND DEVELOPED IN CONJUNCTION WITH THE EDUCATION AND ENGAGEMENT COMMITTEE, COMPOSED OF ONCOLOGISTS, RESEARCHERS, ONCOLOGY NURSES, SOCIAL WORKERS, AND PATIENTS/CAREGIVERS. THE PATIENT EDUCATIONAL PORTFOLIO IS ALSO CRAFTED WITH ASSISTANCE FROM THE FEEDBACK WE RECEIVE FROM OUR COMMUNITY. OUR MATERIALS ARE RATED ON AVERAGE A 4.6/5 ACCORDING TO THE FEEDBACK COLLECTED FROM INDIVIDUALS WHO DOWNLOAD OR ORDER OUR PRINT MATERIALS ON OUR WEBSITE. SAMPLE FEEDBACK INCLUDES: THANK YOU FOR PROVIDING FREE EDUCATIONAL RESOURCES. I AM A THORACIC NURSE NAVIGATOR AND PROVIDE THESE TO ALL OF MY LUNG CANCER PATIENTS. MY PATIENTS LIKE AND APPRECIATE THEM VERY MUCH. THANK YOU SO MUCH FOR PROVIDING INFORMATION TO PEOPLE TRYING TO NAVIGATE A LUNG CANCER DIAGNOSIS AND ALL THE STRESS RELATED TO THE ENTIRE PROCESS. MY MOTHER WAS RECENTLY DIAGNOSED WITH LUNG CANCER. VERY HEARTBREAKING AND A SURPRISE TO US ALL. HEARD NOTHING BUT GOOD REVIEWS ABOUT LCRF SO I LOOK FORWARD TO LEARNING ABOUT EVERYTHING AND I APPRECIATE WHAT YOU ALL DO. I LOVE THE UPDATED LIVING WITH LUNG CANCER BOOKLET. I READ IT FROM COVER TO COVER AND FEEL THAT IT WAS VERY NICELY DONE. IT IS DEFINITELY VERY COMPREHENSIVE IN THAT IT INCLUDES COPING WITH DIAGNOSIS/TREATMENT, INFORMATION ABOUT OUR NEWER TARGETED AND IMMUNOTHERAPIES, AND TREATMENT SIDE-EFFECT MANAGEMENT. GOOD JOB ON YOUR END! LUNG CANCER SUPPORT LINE: OUR LUNG CANCER SUPPORT LINE IS A TOLL-FREE NUMBER (844)-835-4325, AND IS AVAILABLE TO ANYONE AFFECTED BY LUNG CANCER, PRIMARILY LUNG CANCER PATIENTS AND CAREGIVERS. THE SUPPORT LINE OPERATES MONDAY-FRIDAY 9AM-5PM ET AND IS EQUIPPED WITH EXTENSIVE AND UP-TO-DATE RESOURCE GUIDES FOR COMMON NEEDS AND SERVICES FOR LUNG CANCER PATIENTS SUCH AS FINANCIAL ASSISTANCE, TRANSPORTATION OR LODGING TO/FROM MEDICAL APPOINTMENTS, SUPPORT GROUPS, AND MUCH MORE. LUNG CANCER PATIENTS AND THEIR CAREGIVERS MAY CALL OR EMAIL THE PROGRAM AS OFTEN AS THEY WISH, AND THE SERVICE IS OFFERED FREE OF CHARGE. THE LUNG CANCER SUPPORT LINE HELPS FILL AN UNMET NEED BY PROVIDING PERSONALIZED, ONE-ON-ONE SUPPORT TO CALLERS WHO ARE FACING THE CHALLENGES OF LUNG CANCER. IN 2023, WE HAD OVER 1,000 INQUIRIES COME IN THROUGH THE SUPPORT LINE. OVER HALF OF CALLERS ARE NEWLY DIAGNOSED PATIENTS OR CAREGIVERS OF THOSE WHO ARE RECENTLY DIAGNOSED, PROVING THAT THE SUPPORT LINE PROVIDES A TIMELY SERVICE FOR THOSE SEEKING SUPPORT. MANY SUPPORT LINE INQUIRIES ALSO COME IN FROM HEALTHCARE INSTITUTIONS OR COMMUNITY-BASED INSTITUTIONS LOOKING FOR RESOURCES FOR THEIR PATIENTS. OUR CONTINUED GOAL FOR THE SUPPORT LINE IS TO STRENGTHEN OUR COMMUNICATION WITH THOSE WHO ARE NEWLY DIAGNOSED AND ENGAGED IN OUR EDUCATIONAL PROGRAMS. WE ALSO HOPE TO INCREASE OUR SUPPORT LINE REACH BY 10% OVER THE NEXT YEAR VIA TARGETED OUTREACH AND PROMOTION OF OUR SERVICES. THROUGH THE SUPPORT LINE, WE: PROVIDE A QUALITY SERVICE TO PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS, BY OFFERING SUPPORT IN THEIR AREA OF NEED DURING ONE-ON-ONE INTERACTIONS; EMPOWER PATIENTS AND CAREGIVERS THROUGH CONNECTIONS TO RESOURCES (EDUCATION, ASSISTANCE, AND SUPPORT); ENHANCE PATIENTS AND CAREGIVERS' UNDERSTANDING OF LUNG CANCER; INCREASE NUMBER OF SUPPORT INQUIRIES AND TOTAL NUMBER OF INTERACTIONS BETWEEN LCRF SUPPORT SERVICES STAFF AND PERSON SEEKING SUPPORT; AND INCREASE SUPPORT TO UNDERSERVED POPULATIONS BY DEVELOPING RELEVANT RESOURCE GUIDES THAT ADDRESS THE NEEDS OF SPECIFIC UNDERSERVED POPULATIONS (I.E.: PEOPLE OF COLOR, UNINSURED, LGBTQ+, NON-ENGLISH SPEAKING, CAREGIVERS, YOUNG ADULTS). PATIENT EDUCATION PROGRAMMING (VIRTUAL AND IN-PERSON): BARRIERS TO ACCESSING UP-TO-DATE, EXPERT INFORMATION ON LUNG CANCER RESEARCH ADVANCEMENTS AND TREATMENTS ARE EVIDENT BASED ON STIGMA SURROUNDING LUNG CANCER. OUR PATIENT EDUCATION PROGRAMMING AIMS TO INCREASE THE ACCESSIBILITY OF DISEASE AWARENESS AND INFORMATION TO THE LUNG CANCER COMMUNITY BY CREATING EVENTS WHERE LUNG CANCER RESEARCHERS, CLINICIANS, AND OTHER EXPERTS DISCUSS SCIENTIFIC ADVANCEMENT, IMPORTANT UPDATES IN TREATMENTS, AS WELL AS INFORMATION FOR IMPROVING QUALITY OF LIFE WHILE RECEIVING TREATMENT. LCRF ALSO AIMS TO HOST TOPICS THAT WOULD SPECIFICALLY HELP SUPPORT UNDERSERVED POPULATIONS, SUCH AS PEOPLE OF COLOR, THOSE IN LOW SOCIOECONOMIC GROUPS, RURAL DEMOGRAPHICS, AND SPANISH-SPEAKING POPULATIONS, ALL OF WHICH EXPERIENCE A RANGE OF HEALTH DISPARITIES. ATTENDEES, BOTH VIRTUAL AND IN-PERSON, HAVE THE OPPORTUNITY TO LEARN ABOUT LUNG CANCER, TREATMENT OPTIONS AND ADVANCES IN RESEARCH, CLINICAL TRIALS AND AVAILABLE RESOURCES. THEY CAN POSE QUESTIONS TO LUNG CANCER EXPERTS, SHARE THEIR OWN PERSONAL EXPERIENCE, AND ENGAGE WITH THEIR PEERS, FORGING CONNECTIONS AND SUPPORT. THIS PROGRAM ALLOWS PATIENTS AND THEIR FAMILIES TO BECOME MORE INFORMED ABOUT LUNG CANCER AND THEIR OPTIONS FOR NAVIGATING LIFE WITH THEIR DISEASE. THE LEARNING OBJECTIVES OF OUR EDUCATIONAL PROGRAMS ARE: 1. PROVIDE UP-TO-DATE EDUCATION AND INFORMATION ABOUT LUNG CANCER DIAGNOSIS AND TREATMENT, SO OUR AUDIENCE HAS A RELIABLE SOURCE TO TURN TO FOR ACCURATE AND TIMELY INFORMATION; 2. INFORM ABOUT NEW ADVANCEMENTS IN THE FIELD OF LUNG CANCER RESEARCH AND THE TREATMENT LANDSCAPE; 3. PROVIDE OPPORTUNITY FOR DIALOGUE AND A SENSE OF CONNECTION AND COMMUNITY; 4. HIGHLIGHT RESEARCH ADVANCEMENTS, NEWLY DISCOVERED TREATMENT OPTIONS, BEST PRACTICES AND STANDARDS OF CARE FOR PATIENTS UNDERGOING TREATMENT, AND PSYCHOSOCIAL SUPPORT FOR PATIENTS AND THEIR CAREGIVERS; 5. ENSURE AWARENESS OF AND ACCESS TO IMPORTANT LUNG CANCER RESOURCES AND PROGRAMS OFFERED THROUGH LCRF AND ITS PARTNERS. SINCE ITS INCEPTION IN MARCH 2020, WE'VE HAD OVER 7,500 REGISTRANTS FOR OUR #TOGETHERSEPARATELY VIRTUAL EVENTS WITH AN AVERAGE ATTENDANCE RECORD OF OVER 100 INDIVIDUALS PER WEBINAR. MOST OF THE ATTENDEES IN THIS SERIES ARE LUNG CANCER PATIENTS, SURVIVORS, ADVOCATES, CAREGIVERS, AND COMMUNITY PROVIDERS. OUR GOAL IS TO CONTINUE THE SERIES, WHILE FOCUSING ON THE BIGGEST AREAS OF UNMET NEEDS IN THE LUNG CANCER COMMUNITY. ADDITIONALLY, SINCE 2022, WE'VE REINTRODUCED OUR IN-PERSON PROGRAMMING WITH THE LAUNCH OF OUR LCRF TOGETHER IN-PERSO FORM 990, PART III LINE 4B, PROGRAM SERVICE ACCOMPLISHMENTS, CONTINUED: ADDITIONALLY, SINCE 2022, WE'VE REINTRODUCED OUR IN-PERSON PROGRAMMING WITH THE LAUNCH OF OUR LCRF TOGETHER IN-PERSON EDUCATIONAL PROGRAM SERIES. WE HOSTED OUR FIRST LCRF TOGETHER PROGRAM IN CHICAGO, ILLINOIS ON JUNE 28, 2022. THIS EVENT HAD OVER 50 PEOPLE IN ATTENDANCE, INCLUDING PATIENTS AND CAREGIVERS, THOSE WHO HAVE LOST A LOVED ONE, AS WELL AS HEALTHCARE PROFESSIONALS AND INDUSTRY SPONSORS. FORM 990, PART VI, SECTION A, LINE 2 MARY ANN TIGHE AND AARON M. TIGHE - FAMILY RELATIONSHIP MARY ANN TIGHE AND RAYMOND E. CHALME - BUSINESS RELATIONSHIP FORM 990, PART VI, SECTION B, LINE 11B A DRAFT OF THE RETURN IS REVIEWED FIRST BY THE EXECUTIVE COMMITTEE AND THEN BY THE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD REVIEWS THE CONFLICT OF INTEREST POLICY ANNUALLY, AND ASKS ALL BOARD MEMBERS AND EMPLOYEES TO DISCLOSE ANY CONFLICTS OR POTENTIAL CONFLICTS. IN ADDITION, ALL CONTRACTS ARE REVIEWED FOR KNOWN OR POTENTIAL CONFLICTS BY THE EXECUTIVE DIRECTOR, SR. DIRECTOR FINANCE & ADMINISTRATION AND THE EXECUTIVE COMMITTEE ON AN ON-GOING BASIS. FORM 990, PART VI, SECTION B, LINE 15 THE EXECUTIVE COMMITTEE OF THE BOARD LOOKS AT COMPENSATION SURVEYS AND ALSO COMPARES SALARIES IN SIMILAR ORGANIZATIONS TO DETERMINE THE REASONABLENESS OF SALARIES FOR KEY EMPLOYEES. THE EXECUTIVE COMMITTEE ALSO CONSIDERS OTHER PERFORMANCE-BASED CRITERIA WHICH INCLUDES A WRITTEN PERFORMANCE APPRAISAL OF THE EXECUTIVE DIRECTOR. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE. ALL OTHER DOCUMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON RECEIPT OF A WRITTEN REQUEST. FORM 990, PART XI, LINE 9: RETURNED GRANT FUNDS 87,950.